

Peter J Neumann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7767994/publications.pdf>

Version: 2024-02-01

160
papers

7,314
citations

76294

40
h-index

62565

80
g-index

167
all docs

167
docs citations

167
times ranked

8345
citing authors

#	ARTICLE	IF	CITATIONS
1	Do Cost-Effectiveness Analyses Account for Drug Genericism? A Literature Review and Assessment of Implications. <i>Value in Health</i> , 2022, 25, 59-68.	0.1	13
2	Are Medical Devices Cost-Effective?. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 235-241.	1.0	1
3	The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies. <i>Value in Health</i> , 2022, 25, 1336-1343.	0.1	4
4	A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional Issues. <i>Value in Health</i> , 2022, 25, 1298-1306.	0.1	10
5	Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions. <i>Genetics in Medicine</i> , 2022, 24, 1349-1361.	1.1	25
6	The History and Future of the "SPOR Value Flower": Addressing Limitations of Conventional Cost-Effectiveness Analysis. <i>Value in Health</i> , 2022, 25, 558-565.	0.1	24
7	Addressing Challenges to Alternative Payment Models for New Alzheimer's Disease Therapies for US Commercial Payers. <i>Pharmacoeconomics</i> , 2022, 40, 647-652.	1.7	2
8	Racial and Ethnic Differences in Hospice Use and Hospitalizations at End-of-Life Among Medicare Beneficiaries With Dementia. <i>JAMA Network Open</i> , 2022, 5, e2216260.	2.8	27
9	Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic. <i>Health Affairs</i> , 2021, 40, 53-61.	2.5	29
10	An Evidence Review of Low-Value Care Recommendations: Inconsistency and Lack of Economic Evidence Considered. <i>Journal of General Internal Medicine</i> , 2021, 36, 3448-3455.	1.3	12
11	The Right Price. , 2021, , .		9
12	For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 650-659.	0.5	4
13	Value-based drug pricing in the Biden era: Opportunities and prospects. <i>Health Services Research</i> , 2021, 56, 1093-1099.	1.0	3
14	Dementia Diagnosis Disparities by Race and Ethnicity. <i>Medical Care</i> , 2021, 59, 679-686.	1.1	64
15	Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic. <i>Pharmacoeconomics</i> , 2021, 39, 1201-1208.	1.7	8
16	Toward Better Data Dashboards for US Drug Value Assessments. <i>Value in Health</i> , 2021, 24, 1484-1489.	0.1	4
17	Modelling the value of innovative treatments for Alzheimer's disease in the United States. <i>Journal of Medical Economics</i> , 2021, 24, 764-769.	1.0	9
18	Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines. <i>Vaccine</i> , 2021, 39, 6727-6734.	1.7	5

#	ARTICLE	IF	CITATIONS
19	Valuing Alzheimer Disease Therapiesâ€”Considering Costs and Benefits Beyond the Patient. JAMA Network Open, 2021, 4, e2131913.	2.8	4
20	Drug-Pricing Debate Redux â€” Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?. New England Journal of Medicine, 2021, 385, 1923-1924.	13.9	11
21	Cost-Effectiveness Analysis in Pediatric Imaging: The Evidence (or Lack Thereof) Thus Far. Journal of the American College of Radiology, 2020, 17, 452-461.	0.9	7
22	Measuring â€œEconomic Effectsâ€”in Valuing Therapies: An Application to COVID-19 in China. Value in Health, 2020, 23, 1405-1408.	0.1	12
23	The Economic and Public Health Imperatives Around Making Potential Coronavirus Diseaseâ€”2019 Treatments Available and Affordable. Value in Health, 2020, 23, 1427-1431.	0.1	8
24	Perspective and Costing in Cost-Effectiveness Analysis, 1974â€”2018. Pharmacoeconomics, 2020, 38, 1135-1145.	1.7	109
25	Preparing the healthâ€”care system to pay for new Alzheimer's drugs. Alzheimer's and Dementia, 2020, 16, 1568-1570.	0.4	12
26	Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans. JAMA - Journal of the American Medical Association, 2020, 323, 1972.	3.8	20
27	Balancing Value with Affordability: Cell Immunotherapy for Cancer Treatment in the U.S.. Oncologist, 2020, 25, e1117-e1119.	1.9	5
28	Growth and capacity for costâ€”effectiveness analysis in Africa. Health Economics (United Kingdom), 2020, 29, 945-954.	0.8	34
29	Are low and middle-income countries prioritising high-value healthcare interventions?. BMJ Global Health, 2020, 5, e001850.	2.0	13
30	Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?. International Journal of Technology Assessment in Health Care, 2020, 36, 96-103.	0.2	26
31	Racial and Ethnic Differences in Knowledge About One's Dementia Status. Journal of the American Geriatrics Society, 2020, 68, 1763-1770.	1.3	32
32	Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs. Journal of General Internal Medicine, 2020, 35, 2629-2636.	1.3	29
33	Prevention of non-communicable disease: best buys, wasted buys, and contestable buys. BMJ, The, 2020, 368, m141.	3.0	25
34	Dementia diagnosis disparities by race and ethnicity. Alzheimer's and Dementia, 2020, 16, e043183.	0.4	14
35	Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug Coverage. Health Affairs, 2019, 38, 1882-1886.	2.5	13
36	Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 1185-1192.	0.5	5

#	ARTICLE	IF	CITATIONS
37	Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?. Value in Health, 2019, 22, 1396-1401.	0.1	3
38	Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy. Value in Health, 2019, 22, 661-668.	0.1	61
39	Taking stock of cost-effectiveness analysis of healthcare in China. BMJ Global Health, 2019, 4, e001418.	2.0	19
40	Publication of Decision Model Source Code: Attitudes of Health Economics Authors. Pharmacoeconomics, 2019, 37, 1409-1410.	1.7	9
41	Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions. Pharmacoeconomics, 2019, 37, 597-608.	1.7	46
42	Adherence to the iDSI reference case among published cost-per-DALY averted studies. PLoS ONE, 2019, 14, e0205633.	1.1	27
43	Preapproval Information Exchange: Perspectives of U.S. Population Health Decision Makers on Preferences for Early Engagement with Investigational Therapies. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 164-173.	0.5	6
44	Comparative Modeling to Inform Health Policy Decisions: A Step Forward. Annals of Internal Medicine, 2019, 171, 851.	2.0	6
45	Cost-Effectiveness Studies in the ICU: A Systematic Review*. Critical Care Medicine, 2019, 47, 1011-1017.	0.4	34
46	Targeted Incentive Programs For Lung Cancer Screening Can Improve Population Health And Economic Efficiency. Health Affairs, 2019, 38, 60-67.	2.5	8
47	A Health Economics Approach to US Value Assessment Frameworks—Introduction: An ISPOR Special Task Force Report [1]. Value in Health, 2018, 21, 119-123.	0.1	102
48	Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. Value in Health, 2018, 21, 759-761.	0.1	108
49	Review of Recent US Value Frameworks—A Health Economics Approach: An ISPOR Special Task Force Report [6]. Value in Health, 2018, 21, 155-160.	0.1	52
50	A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]. Value in Health, 2018, 21, 161-165.	0.1	113
51	Insurance coverage for genomic tests. Science, 2018, 360, 278-279.	6.0	18
52	Accelerating Alzheimer's disease drug innovations from the research pipeline to patients. Alzheimer's and Dementia, 2018, 14, 833-836.	0.4	25
53	Patient Variability Seldom Assessed in Cost-effectiveness Studies. Medical Decision Making, 2018, 38, 487-494.	1.2	16
54	A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures. Value in Health, 2018, 21, 400-406.	0.1	4

#	ARTICLE	IF	CITATIONS
55	An Overview of Value, Perspective, and Decision Contextâ€”A Health Economics Approach: An ISPOR Special Task Force Report [2]. <i>Value in Health</i> , 2018, 21, 124-130.	0.1	132
56	Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer Patients. <i>Value in Health</i> , 2018, 21, 304-309.	0.1	8
57	Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 1240-1246.	0.5	4
58	Future Directions for Cost-effectiveness Analyses in Health and Medicine. <i>Medical Decision Making</i> , 2018, 38, 767-777.	1.2	58
59	QALYs in 2018â€”Advantages and Concerns. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2473.	3.8	113
60	Specialty Drug Coverage Varies Across Commercial Health Plans In The US. <i>Health Affairs</i> , 2018, 37, 1041-1047.	2.5	45
61	Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 632-642.	0.5	35
62	Risk-Targeted Lung Cancer Screening. <i>Annals of Internal Medicine</i> , 2018, 168, 161.	2.0	85
63	A Call for Open-Source Cost-Effectiveness Analysis. <i>Annals of Internal Medicine</i> , 2018, 168, 529.	2.0	7
64	Risk-Targeted Lung Cancer Screening. <i>Annals of Internal Medicine</i> , 2018, 169, 200.	2.0	1
65	Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures. <i>Gates Open Research</i> , 2018, 2, 5.	2.0	24
66	Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures. <i>Gates Open Research</i> , 2018, 2, 5.	2.0	15
67	Cost-Effectiveness Analysis 2.0. <i>New England Journal of Medicine</i> , 2017, 376, 203-205.	13.9	100
68	Updated Recommendations for Cost-effectiveness Studiesâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 90.	3.8	3
69	Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 227-235.	1.0	1
70	Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks. <i>Value in Health</i> , 2017, 20, 193-199.	0.1	18
71	The influence of time horizon on results of cost-effectiveness analyses. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 615-623.	0.7	51
72	Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models. <i>Medical Decision Making</i> , 2017, 37, 790-801.	1.2	9

#	ARTICLE	IF	CITATIONS
73	A Review of Empirical Analyses of Disinvestment Initiatives. <i>Value in Health</i> , 2017, 20, 909-918.	0.1	29
74	Hospitalizations for ambulatory care sensitive conditions and unplanned readmissions among Medicare beneficiaries with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 1174-1178.	0.4	41
75	ICER's Revised Value Assessment Framework for 2017-2019: A Critique. <i>Pharmacoeconomics</i> , 2017, 35, 977-980.	1.7	13
76	Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process. <i>Health Affairs</i> , 2017, 36, 1408-1415.	2.5	20
77	A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer's Disease Patients. <i>Neurology and Therapy</i> , 2017, 6, 131-144.	1.4	22
78	The Cost-Effectiveness of Oral Nutrition Supplementation for Malnourished Older Hospital Patients. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 75-83.	1.0	44
79	Willingness to Pay for a Newborn Screening Test for Spinal Muscular Atrophy. <i>Pediatric Neurology</i> , 2017, 66, 69-75.	1.0	8
80	[P4557]: FAMILY AND CAREGIVER SPILLOVER EFFECTS IN ALZHEIMER'S DISEASE COST-EFFECTIVENESS ANALYSES. <i>Alzheimer's and Dementia</i> , 2017, 13, P1565.	0.4	1
81	When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs. <i>PLoS Medicine</i> , 2017, 14, e1002397.	3.9	68
82	Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 685-698.	0.5	55
83	Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Before and After Diagnosis. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 1549-1557.	1.3	82
84	International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework. <i>Journal of Clinical Oncology</i> , 2016, 34, 2936-2937.	0.8	12
85	The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh. <i>Health Research Policy and Systems</i> , 2016, 14, 86.	1.1	8
86	P2-433: 30-Day Hospital Readmissions Among Medicare Beneficiaries With Alzheimer's Disease and Related Dementias Prior to and Following Diagnosis. , 2016, 12, P811-P812.		1
87	O21101: National Estimates of Potentially Avoidable Hospitalizations among Medicare Beneficiaries with Alzheimer's Disease and Related Dementias. <i>Alzheimer's and Dementia</i> , 2016, 12, P253.	0.4	6
88	Cost-Effectiveness Analysis Expands its Reach Worldwide. <i>Value in Health Regional Issues</i> , 2016, 10, 101-102.	0.5	5
89	The Role of Decision Models in Health Care Policy. <i>Medical Decision Making</i> , 2016, 36, 666-679.	1.2	2
90	A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 33.	3.0	11

#	ARTICLE	IF	CITATIONS
91	Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study. <i>Pharmacoeconomics</i> , 2016, 34, 1255-1265.	1.7	8
92	Lack of Cost-Effectiveness Analyses to Address Healthy People 2020 Priority Areas. <i>American Journal of Public Health</i> , 2016, 106, 2205-2207.	1.5	4
93	Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1093.	3.8	2,149
94	Cost-effectiveness of adherence-enhancing interventions: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 67-84.	0.7	24
95	Cost-Utility Analysis of Cancer Prevention, Treatment, and Control. <i>American Journal of Preventive Medicine</i> , 2016, 50, 241-248.	1.6	48
96	A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. <i>PLoS ONE</i> , 2016, 11, e0168512.	1.1	61
97	CHANGING FACE OF MEDICARE'S NATIONAL COVERAGE DETERMINATIONS FOR TECHNOLOGY. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 347-354.	0.2	5
98	Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. <i>Blood</i> , 2015, 125, 1866-1869.	0.6	32
99	Price and value in cancer care. <i>Cancer</i> , 2015, 121, 4097-4098.	2.0	0
100	When Does FDAMA Section 114 Apply? Ten Case Studies. <i>Value in Health</i> , 2015, 18, 682-689.	0.1	3
101	Comparative changes in treatment practices and clinical outcomes following implementation of a prospective payment system: the STEPPS study. <i>BMC Nephrology</i> , 2015, 16, 67.	0.8	11
102	The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 931-940.	0.7	21
103	Medicare's use of cost-effectiveness analysis for prevention (but not for treatment). <i>Health Policy</i> , 2015, 119, 156-163.	1.4	19
104	Medicare Is Scrutinizing Evidence More Tightly For National Coverage Determinations. <i>Health Affairs</i> , 2015, 34, 253-260.	2.5	28
105	Cost-Utility Analyses in Diabetes: A Systematic Review and Implications from Real-World Evidence. <i>Value in Health</i> , 2015, 18, 308-314.	0.1	32
106	The Changing Face of the Cost-Utility Literature, 1990-2012. <i>Value in Health</i> , 2015, 18, 271-277.	0.1	85
107	The State of Cost-Utility Analyses in Asia: A Systematic Review. <i>Value in Health Regional Issues</i> , 2015, 6, 7-13.	0.5	14
108	The lag from FDA approval to published cost-utility evidence. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 399-402.	0.7	8

#	ARTICLE	IF	CITATIONS
109	Measuring the Value of Prescription Drugs. <i>New England Journal of Medicine</i> , 2015, 373, 2595-2597.	13.9	133
110	Private Payers Disagree With Medicare Over Medical Device Coverage About Half The Time. <i>Health Affairs</i> , 2015, 34, 1376-1382.	2.5	33
111	An Assessment of the Methodological Quality of Published Network Meta-Analyses: A Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0121715.	1.1	28
112	Is the high cost of CML care "worth it"? <i>Journal of Clinical Oncology</i> , 2015, 33, e17801-e17801.	0.8	1
113	The economic value of personalized medicine tests: what we know and what we need to know. <i>Genetics in Medicine</i> , 2014, 16, 251-257.	1.1	91
114	Is the US "leading from behind" on health policy?. <i>European Journal of Health Economics</i> , 2014, 15, 113-116.	1.4	2
115	Despite High Costs, Specialty Drugs May Offer Value For Money Comparable To That Of Traditional Drugs. <i>Health Affairs</i> , 2014, 33, 1751-1760.	2.5	22
116	The Progression of Alzheimer's Disease Can Be Assessed with a Short Version of the CERAD Neuropsychological Battery: The Kuopio ALSOVA Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 494-508.	0.6	5
117	Oncologists' and family physicians' views on value for money of cancer and congestive heart failure care. <i>Israel Journal of Health Policy Research</i> , 2013, 2, 44.	1.4	10
118	Communicating and Promoting Comparative-Effectiveness Research Findings. <i>New England Journal of Medicine</i> , 2013, 369, 209-211.	13.9	16
119	A survey of individuals in US-based pharmaceutical industry HEOR departments: attitudes on policy topics. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 657-661.	0.7	3
120	Therapies For Advanced Cancers Pose A Special Challenge For Health Technology Assessment Organizations In Many Countries. <i>Health Affairs</i> , 2012, 31, 700-708.	2.5	28
121	Skills of the Trade: The Tufts Cost-Effectiveness Analysis Registry. <i>Journal of Benefit-Cost Analysis</i> , 2012, 3, 1-9.	0.6	23
122	What We Talk about When We Talk about Health Care Costs. <i>New England Journal of Medicine</i> , 2012, 366, 585-586.	13.9	27
123	Medicare's Enduring Struggle to Define "Reasonable and Necessary" Care. <i>New England Journal of Medicine</i> , 2012, 367, 1775-1777.	13.9	49
124	The cost-effectiveness of biopharmaceuticals. <i>MABs</i> , 2012, 4, 281-288.	2.6	14
125	FDA Actions Against Health Economic Promotions, 2002-2011. <i>Value in Health</i> , 2012, 15, 948-953.	0.1	6
126	Willingness to pay for predictive tests with no immediate treatment implications: a survey of US residents. <i>Health Economics (United Kingdom)</i> , 2012, 21, 238-251.	0.8	109

#	ARTICLE	IF	CITATIONS
127	US FDA Modernization Act, Section 114. Pharmacoeconomics, 2011, 29, 687-692.	1.7	11
128	Risk-Sharing Arrangements That Link Payment For Drugs To Health Outcomes Are Proving Hard To Implement. Health Affairs, 2011, 30, 2329-2337.	2.5	90
129	How Long and How Well. Medical Decision Making, 2011, 31, 380-385.	1.2	26
130	What Next for QALYs?. JAMA - Journal of the American Medical Association, 2011, 305, 1806.	3.8	34
131	Medicare and Medical Technology – The Growing Demand for Relevant Outcomes. New England Journal of Medicine, 2010, 362, 377-379.	13.9	69
132	Evaluating HTA principles. International Journal of Technology Assessment in Health Care, 2010, 26, 429-430.	0.2	2
133	Cancer Therapy Costs Influence Treatment: A National Survey Of Oncologists. Health Affairs, 2010, 29, 196-202.	2.5	125
134	Legislating against Use of Cost-Effectiveness Information. New England Journal of Medicine, 2010, 363, 1495-1497.	13.9	222
135	Low-value services in value-based insurance design. American Journal of Managed Care, 2010, 16, 280-6.	0.8	18
136	Is The United States Ready For QALYs?. Health Affairs, 2009, 28, 1366-1371.	2.5	69
137	Are mAbs different?. MAbs, 2009, 1, 29-30.	2.6	1
138	Lessons for Health Technology Assessment: It Is Not Only about the Evidence. Value in Health, 2009, 12, S45-S48.	0.1	21
139	30 Years of Pharmaceutical Cost-Utility Analyses. Pharmacoeconomics, 2009, 27, 861-872.	1.7	67
140	Costing and Perspective in Published Cost-Effectiveness Analysis. Medical Care, 2009, 47, S28-S32.	1.1	107
141	NEUMANN ET AL. RESPOND. American Journal of Public Health, 2009, 99, 776-776.	1.5	0
142	Measuring the Value of Public Health Systems: The Disconnect Between Health Economists and Public Health Practitioners. American Journal of Public Health, 2008, 98, 2173-2180.	1.5	36
143	A strategic plan for integrating cost-effectiveness analysis into the US healthcare system. American Journal of Managed Care, 2008, 14, 185-8.	0.8	17
144	Challenges Ahead For Federal Technology Assessment. Health Affairs, 2007, 26, w150-w152.	2.5	0

#	ARTICLE	IF	CITATIONS
145	Economic Evaluation in the US. <i>Pharmacoeconomics</i> , 2006, 24, 1163-1168.	1.7	27
146	Emerging Lessons From The Drug Effectiveness Review Project. <i>Health Affairs</i> , 2006, 25, W262-W271.	2.5	28
147	Do drug formulary policies reflect evidence of value?. <i>American Journal of Managed Care</i> , 2006, 12, 30-6.	0.8	14
148	The Arrival of Economic Evidence in Managed Care Formulary Decisions. <i>Medical Care</i> , 2005, 43, II-27.	1.1	10
149	Growth and Quality of the Cost-Utility Literature, 1976-2001. <i>Value in Health</i> , 2005, 8, 3-9.	0.1	136
150	Can We Better Prioritize Resources for Cost-Utility Research?. <i>Medical Decision Making</i> , 2005, 25, 429-436.	1.2	40
151	Medicare and Cost-Effectiveness Analysis. <i>New England Journal of Medicine</i> , 2005, 353, 1516-1522.	13.9	219
152	Health Utilities in Alzheimer's Disease and Implications for Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2005, 23, 537-541.	1.7	24
153	Evidence-Based And Value-Based Formulary Guidelines. <i>Health Affairs</i> , 2004, 23, 124-134.	2.5	66
154	Why don't Americans use cost-effectiveness analysis?. <i>American Journal of Managed Care</i> , 2004, 10, 308-12.	0.8	74
155	Do HEDIS measures reflect cost-effective practices?. <i>American Journal of Preventive Medicine</i> , 2002, 23, 276-289.	1.6	19
156	Cost-Utility Analysis. <i>Annals of Internal Medicine</i> , 2001, 134, 626.	2.0	0
157	MEASURING COSTS IN COST-UTILITY ANALYSES. <i>International Journal of Technology Assessment in Health Care</i> , 2000, 16, 111-124.	0.2	102
158	Estimating the Long Term Cost Savings from the Treatment of Alzheimer's Disease: A Modelling Approach. <i>Pharmacoeconomics</i> , 2000, 17, 109.	1.7	3
159	Evaluating and Regulating Pharmacoeconomic Information in the Private Sector. <i>Drug Information Journal</i> , 1998, 32, 525-532.	0.5	0
160	Should Health Insurance Cover Ivf? Issues and Options. <i>Journal of Health Politics, Policy and Law</i> , 1997, 22, 1215-1239.	0.9	50